Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Collection

Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?

Bone Marrow Transplantation volume 43, pages 919–925 (2009)Cite this article

Abstract

Our purpose was to assess success rates in children of achieving optimal hematopoietic progenitor cells (HPCs) harvest after mobilization with 300 μg/kg pegfilgrastim. Between January 2005 and January 2007, 26 children with solid malignancies who were referred for HPC collection were consecutively included. Hematopoietic progenitor cell mobilization consisted of one s.c. injection of 300 μg/kg body weight (BW) of pegfilgrastim. The success criterion was defined as at least 5 × 106 CD34+ cells/kg during the first standard apheresis (less than 3 blood volumes processed (BVP)). After 26 inclusions, the Bayesian analysis gave a mean estimated success rate of 60.7% (95% credibility interval: 42.0–78.0%). The first apheresis allowed the collection of 8.3 × 106 CD34+ cells/kg BW (range 0.6–37.8), with a median of 2.8 BVP (range 1.4–3.0). Overall, the median of CD34+ cells collected was 12.4 × 106/kg (range 2.7–37.8). The cumulative dose of anthracyclin was the only variable associated with the total number of CD34+ collected cells (P<0.05). Mobilization was clinically well tolerated in 20 patients. No drug-related adverse events of grade ⩾3 occurred. We conclude that a single injection of 300 μg/kg pegfilgrastim in the hematological steady state is an efficient and well-tolerated method of HPC mobilization in children with solid malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Merlin E, Piguet C, Auvrignon A, Rubie H, Demeocq F, Kanold J . The pros and cons of split-dose granulocyte colony-stimulating factor alone rather than a single high dose for hematopoietic progenitor cell mobilization in small children (&lt;15 kg) with solid tumors. Haematologica 2006; 91: 1004–1005.

    CAS  PubMed  Google Scholar 

  2. Perez-Duenas B, Alcorta I, Estella J, Rives S, Toll T, Tuset E . Safety and efficacy of high-dose G-CSF (24 microg/kg) alone for PBSC mobilization in children. Bone Marrow Transplant 2002; 30: 987–988.

    Article  CAS  PubMed  Google Scholar 

  3. Kanold J, Berger M, Halle P, Rapatel C, Shoebfer C, de Lumley L et al. Kinetics of hematopoietic progenitor cell release induced by G-CSF-alone in children with solid tumors and leukemias. Bone Marrow Transplant 1998; 21: 59–63.

    Article  CAS  PubMed  Google Scholar 

  4. Sevilla J, Gonzalez-Vicent M, Madero L, Garcia-Sanchez F, Diaz MA . Granulocyte colony-stimulating factor alone at 12 microg/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. Bone Marrow Transplant 2002; 30: 417–420.

    Article  CAS  PubMed  Google Scholar 

  5. Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999; 27: 1724–1734.

    Article  CAS  PubMed  Google Scholar 

  6. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR et al. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 2005; 90: 225–231.

    CAS  PubMed  Google Scholar 

  7. Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005; 35: 33–36.

    Article  CAS  PubMed  Google Scholar 

  8. te Poele EM, Kamps WA, Tamminga RY, Leeuw JA, Postma A, de Bont ES . Pegfilgrastim in pediatric cancer patients. J Pediatr Hematol Oncol 2005; 27: 627–629.

    Article  PubMed  Google Scholar 

  9. Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C . Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma. J Pediatr Hematol Oncol 2005; 27: 449–451.

    Article  PubMed  Google Scholar 

  10. André N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 2007; 18: 277–281.

    Article  PubMed  Google Scholar 

  11. Dallorso S, Berger M, Caviglia I, Emanueli T, Faraci M, Scarso L et al. Prospective single-arm study of pegfilgrastim activity and safety in children with poor-risk malignant tumours receiving chemotherapy. Bone Marrow Transplant 2008; 42: 507–513.

    Article  CAS  PubMed  Google Scholar 

  12. Russel N, Mesters R, Schubert J, Boogaerts M, Johnsen H, del Canizo C . A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93: 405–412.

    Article  Google Scholar 

  13. Kanold J, Halle P, Berger M, Rapatel C, Palcoux JB, Rouzier C et al. Large-volume leukapheresis procedure for peripheral blood progenitor cell collection in children weighing 15 kg or less: efficacy and safety evaluation. Med Pediatr Oncol 1999; 32: 7–10.

    Article  CAS  PubMed  Google Scholar 

  14. Biganzoli L, Untch M, Skacel T, Pico JL . Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 2004; 31: 27–34.

    Article  CAS  PubMed  Google Scholar 

  15. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB . Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 2006; 46: 747–757.

    Article  CAS  PubMed  Google Scholar 

  16. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I . The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213–226.

    Article  CAS  PubMed  Google Scholar 

  17. Kanold J, Halle P, Tchirkov A, Berger M, Giarratana MC, Kobari L et al. Ex vivo expansion of autologous PB CD34+ cells provides a purging effect in children with neuroblastoma. Bone Marrow Transplant 2003; 32: 485–488.

    Article  CAS  PubMed  Google Scholar 

  18. Berry DA . Monitoring accumulating data in a clinical trial. Biometrics 1989; 45: 1197–1211.

    Article  CAS  PubMed  Google Scholar 

  19. Zohar S, Teramukai S, Zhou Y . Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. Contemp Clin Trials 2008; 29: 608–616.

    Article  PubMed  Google Scholar 

  20. Zohar S, Chevret S . The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Stat Med 2001; 20: 2827–2843.

    Article  CAS  PubMed  Google Scholar 

  21. Hill G, Morris E, Fuery M, Hutchins C, Butler J, Grigg A . Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF. Biol Blood Marrow Transplant 2006; 12: 603–607.

    Article  PubMed  Google Scholar 

  22. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514–519.

    Article  CAS  PubMed  Google Scholar 

  23. Halle P, Kanold J, Rapatel C, Boiret N, Berger M, Stephan JL et al. Granulocyte colony-stimulating factor alone at 20 micrograms/kg vs 10 micrograms/kg for peripheral blood stem cell mobilization in children. Pediatr Transplant 2000; 4: 285–288.

    Article  CAS  PubMed  Google Scholar 

  24. Watring NJ, Wagner TW, Stark JJ . Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med 2007; 25: 247–248.

    Article  PubMed  Google Scholar 

  25. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A . Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (G-CSF). A case report and review of the literature. Haematologica 2006; 91: ECR08.

    PubMed  Google Scholar 

  26. Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101: 3862–3867.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Comité Départemental du Puy-de-Dôme de la Ligue Nationale Contre le Cancer. We thank C Cailliot (Amgen, France) for his advice, and the nursing staff of the Unité Bioclinique de Thérapie Cellulaire: Annick Collard, Raymond Eglizot, Valérie Hervé, Caroline Lallemand and Anne Laverroux for their excellent assistance in collections and children's care.

Author information

Authors and Affiliations

  1. CHU Clermont-Ferrand, Centre Régional de Cancérologie et Thérapie Cellulaire Pédiatrique, Hôtel-Dieu, Clermont-Ferrand, France

    E Merlin, C Paillard, P Halle, F Deméocq, C Dubray & J Kanold

  2. Inserm, CIC501, Clermont-Ferrand, France

    E Merlin, C Paillard, P Halle, F Deméocq, C Dubray & J Kanold

  3. Clermont Université, Univ Clermont1, Faculté de Médecine, Clermont-Ferrand, France

    E Merlin, R Veyrat-Masson, G Marceau, C Paillard, V Sapin, P Halle, N Boiret-Dupré, F Deméocq, C Dubray & J Kanold

  4. Département de Biostatistiques et Informatique Médicale, U717 Inserm, Hôpital Saint-Louis, Paris, France

    S Zohar & S Chevret

  5. Institut Cancérologique de la Loire, Service de Pédiatrie, St Etienne, France

    C Jérôme

  6. CHU Clermont-Ferrand, Laboratoires d’Hématologie et de Biochimie, Hôtel-Dieu, Clermont-Ferrand, France

    R Veyrat-Masson, G Marceau, V Sapin & N Boiret-Dupré

  7. Hôpital Trousseau, Service d’Hématologie et d’Oncologie Pédiatrique, Paris, France

    A Auvrignon

  8. Hôpital des Enfants, Unité d’Hémato-Oncologie, Brest, France

    P Le Moine

  9. CHU Rennes, Hématologie Pédiatrique, Rennes, France

    V Gandemer

Authors
  1. E Merlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Zohar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Jérôme
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Veyrat-Masson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Marceau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Paillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A Auvrignon
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Le Moine
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V Gandemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. V Sapin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Halle
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. N Boiret-Dupré
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. S Chevret
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. F Deméocq
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. C Dubray
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. J Kanold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Kanold.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Merlin, E., Zohar, S., Jérôme, C. et al. Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?. Bone Marrow Transplant 43, 919–925 (2009). https://doi.org/10.1038/bmt.2008.412

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.412

Keywords

This article is cited by

Search

Advanced search

Quick links